Literature DB >> 22682288

Broad antibody and T cell reactivity induced by a pneumococcal whole-cell vaccine.

Kristin L Moffitt1, Puja Yadav, Daniel M Weinberger, Porter W Anderson, Richard Malley.   

Abstract

Injecting mice with killed cells of non-capsulated strain RM200 adsorbed on Al(OH)3 (pneumococcal whole-cell vaccine; WCV) reduces nasopharyngeal colonization by capsular serotype 6B and prevents fatal aspiration pneumonia by serotype 3 or serotype 5 strains. To further examine the potential for omni-strain immunity, we here examined a panel of clinical isolates and a library of capsule-switch variants in the TIGR4 background. IgG binding to these bacteria in sera of rabbits injected with WCV or Al(OH)3 alone was assayed by ELISA without and with adsorption with cell-wall polysaccharide, a species-common antigen. The examined strains were 23 primary isolates including at least 10 different MLS types and 13 serotypes; 15 of these strains were invasive isolates, subsequently mouse-passed. Additionally, to investigate the effect of capsulation, TIGR4 strain constructs with the capsulation genes of 20 different serotypes were evaluated. In ELISA all strains showed a large difference in IgG binding due to the immunization, of which most of the antibody typically was not CWPS-adsorbed and presumably directed to exposed protein antigens. Increased binding of IgG in the WCV-immunized serum to the 20 isogenic capsule-switch strains was shown also by flow cytometry. Further, all these 20 strains elicited IL-17A in T cells of WCV-vaccinated mice, a cytokine known to accelerate pneumococcal clearance. Thus WCV induced both humoral and T(H)17 cell-mediated immunity against all tested strains.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22682288      PMCID: PMC3372861          DOI: 10.1016/j.vaccine.2012.01.034

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  28 in total

1.  Rabbit antibodies to the cell wall polysaccharide of Streptococcus pneumoniae fail to protect mice from lethal challenge with encapsulated pneumococci.

Authors:  S C Szu; R Schneerson; J B Robbins
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

2.  Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection?

Authors:  D M Musher; D A Watson; R E Baughn
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

3.  A protective monoclonal antibody that reacts with a novel antigen of pneumococcal teichoic acid.

Authors:  L S McDaniel; W D Waltman; B Gray; D E Briles
Journal:  Microb Pathog       Date:  1987-10       Impact factor: 3.738

4.  Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial.

Authors:  F T Cutts; S M A Zaman; G Enwere; S Jaffar; O S Levine; J B Okoko; C Oluwalana; A Vaughan; S K Obaro; A Leach; K P McAdam; E Biney; M Saaka; U Onwuchekwa; F Yallop; N F Pierce; B M Greenwood; R A Adegbola
Journal:  Lancet       Date:  2005 Mar 26-Apr 1       Impact factor: 79.321

5.  Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens.

Authors:  D E Briles; C Forman; J C Horowitz; J E Volanakis; W H Benjamin; L S McDaniel; J Eldridge; J Brooks
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

6.  Limited role of antibody in clearance of Streptococcus pneumoniae in a murine model of colonization.

Authors:  Tera L McCool; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

7.  Construction of otherwise isogenic serotype 6B, 7F, 14, and 19F capsular variants of Streptococcus pneumoniae strain TIGR4.

Authors:  Krzysztof Trzcinski; Claudette M Thompson; Marc Lipsitch
Journal:  Appl Environ Microbiol       Date:  2003-12       Impact factor: 4.792

8.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

Authors:  Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

9.  Ultrastructural localization of capsules, cell wall polysaccharide, cell wall proteins, and F antigen in pneumococci.

Authors:  U B Skov Sørensen; J Blom; A Birch-Andersen; J Henrichsen
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

10.  A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.

Authors:  Keith P Klugman; Shabir A Madhi; Robin E Huebner; Robert Kohberger; Nontombi Mbelle; Nathaniel Pierce
Journal:  N Engl J Med       Date:  2003-10-02       Impact factor: 91.245

View more
  20 in total

Review 1.  Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity.

Authors:  Richard Malley; Porter W Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-02       Impact factor: 11.205

2.  T(H)17-Mediated Protection against Pneumococcal Carriage by a Whole-Cell Vaccine Is Dependent on Toll-Like Receptor 2 and Surface Lipoproteins.

Authors:  K Moffitt; A Howard; S Martin; E Cheung; M Herd; A Basset; R Malley
Journal:  Clin Vaccine Immunol       Date:  2015-06-03

3.  Promises and pitfalls of live attenuated pneumococcal vaccines.

Authors:  Jason W Rosch
Journal:  Hum Vaccin Immunother       Date:  2014-11-19       Impact factor: 3.452

4.  Th17-Mediated Cross Protection against Pneumococcal Carriage by Vaccination with a Variable Antigen.

Authors:  Kirsten Kuipers; Wouter S P Jong; Christa E van der Gaast-de Jongh; Diane Houben; Fred van Opzeeland; Elles Simonetti; Saskia van Selm; Ronald de Groot; Marije I Koenders; Taj Azarian; Elder Pupo; Peter van der Ley; Jeroen D Langereis; Aldert Zomer; Joen Luirink; Marien I de Jonge
Journal:  Infect Immun       Date:  2017-09-20       Impact factor: 3.441

Review 5.  Pneumococcal whole-cell and protein-based vaccines: changing the paradigm.

Authors:  Michael E Pichichero
Journal:  Expert Rev Vaccines       Date:  2017-12       Impact factor: 5.217

6.  Evaluation of the Role of stat3 in Antibody and TH17-Mediated Responses to Pneumococcal Immunization and Infection by Use of a Mouse Model of Autosomal Dominant Hyper-IgE Syndrome.

Authors:  Kristin Moffitt; Elaine Cheung; John Manis; Richard Malley
Journal:  Infect Immun       Date:  2018-04-23       Impact factor: 3.441

Review 7.  A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health.

Authors:  Roberto Biselli; Roberto Nisini; Florigio Lista; Alberto Autore; Marco Lastilla; Giuseppe De Lorenzo; Mario Stefano Peragallo; Tommaso Stroffolini; Raffaele D'Amelio
Journal:  Biomedicines       Date:  2022-08-22

8.  The Asd(+)-DadB(+) dual-plasmid system offers a novel means to deliver multiple protective antigens by a recombinant attenuated Salmonella vaccine.

Authors:  Wei Xin; Soo-Young Wanda; Xiangmin Zhang; Javier Santander; Giorgio Scarpellini; Karen Ellis; Praveen Alamuri; Roy Curtiss
Journal:  Infect Immun       Date:  2012-08-06       Impact factor: 3.441

Review 9.  Serotype-independent pneumococcal vaccines.

Authors:  Eliane Namie Miyaji; Maria Leonor Sarno Oliveira; Eneas Carvalho; Paulo Lee Ho
Journal:  Cell Mol Life Sci       Date:  2012-12-27       Impact factor: 9.261

10.  Identification of protective pneumococcal T(H)17 antigens from the soluble fraction of a killed whole cell vaccine.

Authors:  Kristin L Moffitt; Richard Malley; Ying-Jie Lu
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.